A randomised, double-blind field trial of ivermectin alone and in combination with albendazole for the treatment of *Mansonella perstans* infections in Uganda

Santa Maria Asio, Paul E. Simonsen, Ambrose W. Onapa

*Kyambogo University, P.O. Box 1, Kyambogo, Kampala, Uganda*

*DBL—Centre for Health Research and Development, Faculty of Life Sciences, University of Copenhagen, Thorvaldsensvej 57, 1871 Frederiksberg C, Denmark*

*Vector Control Division, Ministry of Health, P.O. Box 1661, Kampala, Uganda*

Received 25 August 2008; received in revised form 29 October 2008; accepted 29 October 2008

Available online 9 December 2008

**KEYWORDS**

Filaria; *Mansonella perstans*; Treatment; Ivermectin; Albendazole; Uganda

**Summary**

The effect of a single dose of ivermectin alone (150–200 μg/kg body weight) or in combination with albendazole (total of 400 mg) in *Mansonella perstans* infection was assessed in a randomised, double-blind field trial in two endemic communities in Mukono and Luwero districts of Uganda. No side effects were observed or reported during the first 7 days after treatment. The effect on microfilaraemia was analysed among individuals with ≥20 microfilariae (mf) per 100 μl of blood at baseline, who took the treatment and who attended follow-up examinations at 6 months and 12 months after treatment (48 and 46 in Mukono and 48 and 40 in Luwero for the ivermectin and combination treatment, respectively). In both communities, the combination treatment appeared slightly more effective than ivermectin alone, but the difference was not statistically significant. Both drug regimens were more effective in Luwero than in Mukono, probably owing to different diets in the two areas. However, in general both treatment regimens in both communities had limited effect on microfilarial intensities, and only one individual (given combination treatment in Luwero) was mf-negative at 6 months and 12 months after treatment. [ClinicalTrials.gov identifier: NCT00215280] © 2008 Royal Society of Tropical Medicine and Hygiene. Published by Elsevier Ltd. All rights reserved.